
AI-driven biology attracts major investors, spotlighting NVIDIA and Eli Lilly as key public plays.
Major investors are increasingly focusing on AI-driven biology and longevity, with startups like NewLimit tripling in value. While many of these startups remain private, NVIDIA and Eli Lilly stand out as the main public companies involved, partnering...


